Tyra Biosciences, Inc.

NASDAQ:TYRA

10.24 (USD) • At close March 26, 2025
Bedrijfsnaam Tyra Biosciences, Inc.
Symbool TYRA
Munteenheid USD
Prijs 10.24
Beurswaarde 541,407,488
Dividendpercentage 0%
52-weken bereik 9.93 - 29.6
Industrie Biotechnology
Sector Healthcare
CEO Dr. Todd Harris Ph.D.
Website https://www.tyra.bio

An error occurred while fetching data.

Over Tyra Biosciences, Inc.

Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing

Vergelijkbare Aandelen

Esperion Therapeutics, Inc. logo

Esperion Therapeutics, Inc.

ESPR

1.63 USD

Monte Rosa Therapeutics, Inc. logo

Monte Rosa Therapeutics, Inc.

GLUE

5.49 USD

Belite Bio, Inc logo

Belite Bio, Inc

BLTE

65.21 USD

Regencell Bioscience Holdings Limited logo

Regencell Bioscience Holdings Limited

RGC

38.8 USD

Arcellx, Inc. logo

Arcellx, Inc.

ACLX

70.11 USD

Inotiv, Inc. logo

Inotiv, Inc.

NOTV

2.27 USD

Kodiak Sciences Inc. logo

Kodiak Sciences Inc.

KOD

3.01 USD

MeiraGTx Holdings plc logo

MeiraGTx Holdings plc

MGTX

7.23 USD

Viridian Therapeutics, Inc. logo

Viridian Therapeutics, Inc.

VRDN

14.16 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)